+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Successful control of severe postoperative bleeding with recombinant factor VIIa in a case of refractory idiopathic thrombocytopenic purpura

Successful control of severe postoperative bleeding with recombinant factor VIIa in a case of refractory idiopathic thrombocytopenic purpura

American Journal of Hematology 82(3): 246-247

(PDF emailed within 0-6 h: $19.90)

Accession: 050442791

Download citation: RISBibTeXText

PMID: 16924645

DOI: 10.1002/ajh.20728

Related references

Use of Recombinant Factor VIIa in a Pediatric Patient With Initial Presentation of Refractory Acute Immune Thrombocytopenic Purpura and Severe Bleeding. Journal of Pediatric Pharmacology and Therapeutics 17(3): 274-280, 2012

Control of severe bleeding episode in case of Glanzmann's thrombasthenia refractory to platelet transfusion therapy by administering recombinant factor VIIa. Journal of Ayub Medical College, Abbottabad 21(2): 171-173, 2011

Severe bleeding symptoms in refractory idiopathic thrombocytopenic purpura: a case successfully treated with melatonin. American Journal of Therapeutics 10(2): 135-136, 2003

Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. British Journal of Haematology 120(5): 909-910, 2003

Diminished response to recombinant factor VIIa in a patient with idiopathic thrombocytopenic purpura. Annals of PharmacoTherapy 40(11): 2053-2058, 2006

Deep vein thrombosis after recombinant factor VIIa infusion to control severe recurrent postoperative bleeding. Anesthesiology 104(4): 892-893, 2006

Scientific and logistical challenges in designing the CONTROL trial: recombinant factor VIIa in severe trauma patients with refractory bleeding. Clinical Trials 6(5): 467-479, 2010

Successful treatment with recombinant alpha 2 beta interferon for refractory idiopathic thrombocytopenic purpura. Israel Journal of Medical Sciences 28(6): 390-391, 1992

Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin. American Journal of Hematology 57(1): 85-86, 1998

Successful use of one dose of recombinant factor VIIa to control severe bleeding after emergency aortic arch replacement in deep hypothermic circulatory arrest. Journal of Thoracic and Cardiovascular Surgery 128(6): 941-943, 2004

Successful use of recombinant factor VIIa in a bleeding patient with refractory thrombocytopenia undergoing chemotherapy for acute leukemia. Blood 94(10 SUPPL 1 PART 2): 239b, Nov 15, 1999

Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation. Intensive Care Medicine 30(6): 1232-1234, 2004

Successful use of recombinant factor VIIa in a child with Schoenlein-Henoch purpura presenting with compartment syndrome and severe factor XIII deficiency. Blood Coagulation & Fibrinolysis 24(1): 102-105, 2013

Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. Journal of Cardiothoracic and Vascular Anesthesia 16(5): 615-616, 2002

Refractory bleeding following major surgery of a giant sacrococcygeal teratoma in a premature infant: successful use of recombinant factor VIIa. European Journal of Pediatrics 163(2): 118-119, 2004